Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013747 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
A Phase 1 study of Acne, sponsored by Sanofi Pasteur, a Sanofi Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT07013747: Recruiting Phase 1 study of Acne, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT07013747 is a Phase 1 study of Acne that is actively recruiting participants, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 120 participants, below the 138-participant average among 26 other Acne trials with a reported enrollment target (13% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07013747, a Phase 1 study of Acne, is actively recruiting participants, sponsored by Sanofi Pasteur, a Sanofi Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Acne mRNA vaccine
Study Locations (4)
Florida
- Moore Clinical Research - Brandon- Site Number : 8400007 - Brandon
- Encore Research Group-Jacksonville Center for Clinical Research- Site Number : 8400006 - Jacksonville
California
- Encino Research Center- Site Number : 8400008 - Encino
Louisiana
- DelRicht Research- Site Number : 8400003 - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2029-06-19 |
| Phase | Phase 1 |
What NCT07013747 shows while recruiting
NCT07013747 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 138-participant average among 26 other Acne trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07013747 reports a single indexed study location in Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT07013747 about?
NCT07013747 is a clinical study titled "Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne". The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extensio...
What is the current status of trial NCT07013747?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-07-03. Estimated completion is 2029-06-19.
What conditions does trial NCT07013747 study?
This clinical trial studies the following conditions: Acne.
What interventions are being tested in trial NCT07013747?
The interventions under investigation include: Placebo (OTHER), Acne mRNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07013747?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07013747 being conducted?
This trial has 4 study locations across California, Florida, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07013747's enrollment target sits among peer trials
120 10th of 26 higher than 17 of 26 other Acne trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
RECRUITING · Phase 1
-
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
RECRUITING · Phase 1
-
Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel
COMPLETED · Phase 1
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI